Form 4: Robert Duggan Increases Stake in Pulse Biosciences Through Rights Offering

Robert Duggan, a director and 10% owner of Pulse Biosciences, acquired additional common stock and warrants through the company's rights offering.

Summary

• Robert Duggan, a director and 10% owner of Pulse Biosciences, increased his holdings in the company on July 3, 2024.
• Duggan acquired 5,187,824 shares of common stock directly and 69,020 shares indirectly through Genius 24C Inc., and 49,312 shares indirectly through Blazon Corporation.
• He also acquired warrants to purchase 2,593,912 shares directly and 34,510 warrants indirectly through Genius 24C Inc., and 24,656 warrants indirectly through Blazon Corporation.
• These acquisitions were made through the exercise of subscription rights in Pulse Biosciences' previously announced rights offering.
• The rights offering involved the purchase of units at $10.00 per unit, with each unit containing one share of common stock and two warrants, each warrant allowing the purchase of one-half share of common stock at an exercise price of $11.00 per whole share.

Sentiment

Score: 7

Explanation: Insider buying is generally a positive sign, suggesting confidence in the company's prospects. The rights offering itself is a neutral event, but the participation of a major shareholder like Duggan boosts the sentiment.

Positives

• A director and significant shareholder increasing their stake can be seen as a positive signal.
• The rights offering provides Pulse Biosciences with additional capital.

Future Outlook

The document does not contain specific forward-looking statements beyond the details of the rights offering.

Industry Context

Rights offerings are a common method for companies, particularly in the biotech sector, to raise capital. Insider participation, like Duggan's, is often viewed favorably by investors.

Comparison to Industry Standards

• Comparing Pulse Biosciences' rights offering to similar offerings by companies like Agenus Inc. or Celldex Therapeutics, the terms appear standard for the biotech industry.
• The insider participation rate is a key metric; high participation often signals confidence in the company's future prospects, similar to what was observed in recent offerings by companies such as BioCryst Pharmaceuticals.

Stakeholder Impact

• Shareholders may view Duggan's increased stake positively.
• The capital raised through the rights offering could benefit the company's operations and development programs.

Key Dates